Advertisement
U.S. markets open in 5 hours 30 minutes

Zoetis Inc. (ZTS)

NYSE - NYSE Delayed Price. Currency in USD
170.69-1.88 (-1.09%)
At close: 04:00PM EDT
170.90 +0.21 (+0.12%)
After hours: 07:55PM EDT
  • Dividend

    ZTS announced a cash dividend of 0.432 with an ex-date of Apr. 18, 2024

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close172.57
Open173.74
Bid0.00 x 800
Ask0.00 x 900
Day's Range170.41 - 174.28
52 Week Range151.03 - 201.92
Volume4,919,422
Avg. Volume2,466,086
Market Cap78.153B
Beta (5Y Monthly)0.87
PE Ratio (TTM)33.67
EPS (TTM)5.07
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & Yield1.73 (1.01%)
Ex-Dividend DateApr 18, 2024
1y Target Est225.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-15% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ZTS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Zoetis Inc.
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    20 hours agoArgus Research
View more